Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 2/2010

01-02-2010 | Original Paper

Knockdown of ubiquitin-conjugating enzyme E2C/UbcH10 expression by RNA interference inhibits glioma cell proliferation and enhances cell apoptosis in vitro

Authors: Lei Jiang, Yi Bao, Chun Luo, Guohan Hu, Chengguang Huang, Xuehua Ding, Kehua Sun, Yicheng Lu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 2/2010

Login to get access

Abstract

Purpose

To address the role of ubiquitin-conjugating enzyme, E2C/UbcH10, in astrocytic carcinogenesis.

Methods

Expression pattern of UbcH10 in U251 glioma cells was evaluated by immunohistochemistry and western blot. RNA interference was employed to downregulate UbcH10 expression in U251 cell line. The effect of UbcH10 silencing on cell proliferation was assessed by MTT assay and cell cycle analysis. Cell apoptosis was determined by flow cytometry, TUNEL staining and western blot.

Results

Levels of UbcH10 protein were significantly upregulated in U251 cells compared with normal brain tissues. Marked immunoreactivity for UbcH10 was demonstrated in the cytoplasm of U251 glioma cells, especially in the mitotic cells. The growth rate of U251 cells was significantly inhibited by depletion of UbcH10 by short interference RNA. Further, UbcH10 RNAi induced apoptosis through induction of Bax and p53, downregulation of Bcl-2 and G2/M arrest of the cell cycle.

Conclusion

These data imply that knocking-down UbcH10 protein expression may represent a potential therapeutic option for glioma.
Literature
Berlingieri MT, Pallante P, Sboner A et al (2007a) UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer 43:2729–2735PubMed
Berlingieri MT, Pallante P, Guida M et al (2007b) UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. Oncogene 26:2136–2140CrossRefPubMed
Ieta K, Ojima E, Tanaka F et al (2007) Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer 121:33–38CrossRefPubMed
Jiang L, Huang CG, Lu YC et al (2008) Expression of ubiquitin-conjugating enzyme E2C/UbcH10 in astrocytic tumors. Brain Res 27:161–166CrossRef
King RW, Deshaies RJ, Peters JM, Kirschner MW (1996) How proteolysis drives the cell cycle. Science 274:1652–1659CrossRefPubMed
Kleihues P, Louis DN, Scheithauer BW et al (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215–225PubMed
Lin Y, Hwang WC, Basavappa R (2002) Structural and functional analysis of the human mitotic-specific ubiquitin-conjugating enzyme, UbcH10. J Biol Chem 277:21913–21921CrossRefPubMed
Lin J, Raoof DA, Wang Z et al (2006) Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. Neoplasia 8:1062–1071CrossRefPubMed
Midgley CA, Desterro JM, Saville MK et al (2000) An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 19:2312–2323CrossRefPubMed
Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A (2003) UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res 63:4167–4173PubMed
Pallante P, Berlingieri MT, Troncone G et al (2005) UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br J Cancer 93:464–471CrossRefPubMed
Rape M, Reddy SK, Kirschner MW (2006) The processivity of multiubiquitination by the APC determines the order of substrate degradation. Cell 124:89–103CrossRefPubMed
Reddy SK, Rape M, Margansky WA, Kirschner MW (2007) Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation. Nature 446:921–925CrossRefPubMed
Skibbens RV, Hieter P (1998) Kinetochores and the checkpoint mechanism that monitors for defects in the chromosome segregation machinery. Annu Rev Genet 32:307–337CrossRefPubMed
Smits VA, Medema RH (2001) Checking out the G(2)/M transition. Biochim Biophys Acta 1519:1–12PubMed
Townsley FM, Aristarkhov A, Beck S, Hershko A, Ruderman JV (1997) Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad Sci USA 94:2362–2367CrossRefPubMed
Vassilev LT, Vu BT, Graves B et al (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844–848CrossRefPubMed
Wagner KW, Sapinoso LM, El-Rifai W et al (2004) Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene 23:6621–6629CrossRefPubMed
Metadata
Title
Knockdown of ubiquitin-conjugating enzyme E2C/UbcH10 expression by RNA interference inhibits glioma cell proliferation and enhances cell apoptosis in vitro
Authors
Lei Jiang
Yi Bao
Chun Luo
Guohan Hu
Chengguang Huang
Xuehua Ding
Kehua Sun
Yicheng Lu
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 2/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-009-0651-z

Other articles of this Issue 2/2010

Journal of Cancer Research and Clinical Oncology 2/2010 Go to the issue

Original Paper

Posttreatment surveillance after paraaortic radiotherapy for stage I seminoma: a systematic analysis

Original Paper

The serum levels of soluble interleukin-2 receptor α and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas

Original Paper

Genetic variants A1826H and D2937Y in GAG-β domain of versican influence susceptibility to intestinal-type gastric cancer

Review

Controversies concerning the application of brachytherapy in central nervous system tumors

Original Paper

Aberrant p16INK4a methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity

Erratum

Erratum to: The serum levels of soluble interleukin-2 receptor α and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits